Loss to follow-up occurs at all stages in the diagnostic and follow-up period among HIV-infected patients in Guinea-Bissau: a 7-year retrospective cohort study

Bo Langhoff Hønge,1,2 Sanne Jespersen,1,2 Pernille Bejer Nordentoft,1,2 Candida Medina,3 David da Silva,3 Zacarias José da Silva,1,4 Lars Østergaard,2 Alex Lund Laursen,5 Christian Wejse,1,2,5 for the Bissau HIV cohort study group

ABSTRACT

Objectives: To describe loss to follow-up (LTFU) at all stages of the HIV programme.

Design: A retrospective cohort study.

Setting: The HIV clinic at Hospital National Simão Mendes in Bissau, Guinea-Bissau.

Participants: A total of 4080 HIV-infected patients.

Outcome measures: Baseline characteristics, percentages and incidence rates of LTFU as well as LTFU risk factors at four different stages: immediately after HIV diagnosis (stage 1), after the first CD4 cell count and before a follow-up consultation (stage 2), after a follow-up consultation for patients not eligible for antiretroviral treatment (ART; stage 3) and LTFU among patients on ART (stage 4).

Results: Almost one-third of the patients were lost to the programme before the first consultation where ART initiation is decided; during the 7-year observation period, more than half of the patients had been lost to follow-up (overall incidence rate=51.1 patients lost per 100 person-years). Age below 30 years at inclusion was a risk factor for LTFU at all stages of the HIV programme. The biggest risk factors were body mass index <18.5 kg/m² (stage 1), after the first CD4 cell count and before a follow-up consultation (stage 2), after a follow-up consultation for patients not eligible for antiretroviral treatment (ART; stage 3) and LTFU among patients on ART (stage 4).

Conclusions: In this study, LTFU constituted a major problem, and this may apply to other similar ART facilities. More than half of the patients were lost to follow-up shortly after enrolment, possibly implying a high mortality. Thus, retention should be given a high priority.

INTRODUCTION

An estimated 34 million people are infected with HIV and the number is growing. Sub-Saharan Africa is the most affected region, and in some areas antiretroviral treatment (ART) is not available. The coverage of ART is lowest in West and Central Africa where only 30% of the patients in need of ART actually receive it.1 ART has significantly reduced mortality and improved life expectancy of HIV-infected patients,2 but the success critically depends on regular patient follow-up.3 ART requires a large commitment from the patient and without good adherence viral resistance will develop.4,5 Adherence to treatment may be considered more important than the potency of any ART regimen.6 Loss to follow-up (LTFU) of HIV-infected patients is closely related to ART adherence and is becoming an increasing problem in sub-Saharan Africa as ART programmes expand and staff-to-patient ratios decrease.7,8 In a systematic review of ART in sub-Saharan Africa, the authors found that up to 40% of patients were lost to follow-up, with large variation in retention rates between programmes.9 The risk of LTFU is usually highest during the first 6 months after starting ART.8 Furthermore, mortality among patients lost to follow-up in sub-Saharan settings has been reported to range from 20% to 87%.3 This implies that standard survival analyses that censor...
follow-up time at the last visit to an HIV clinic will underestimate the overall mortality.\textsuperscript{10,11}

Regular monitoring is needed to determine when to start ART,\textsuperscript{12,13} and high rates of LTFU before this initiation have been reported in several African settings.\textsuperscript{14–16} However, little information is available about LTFU in patients not eligible for ART and the outcome of these patients in sub-Saharan Africa.

The term ‘loss to programme’ covers patient mortality, LTFU and patients transferring to another HIV clinic. A recent meta-analysis of loss to programme in sub-Saharan Africa has described that patients may become lost to follow-up at different stages. Going through six studies with a total inclusion of 58,746 patients diagnosed with HIV, the authors found that 72\% of the patients had a CD4 cell count measured, 40\% were eligible for ART and only 25\% of the patients initiated ART.\textsuperscript{17} A systematic review found large variations in LTFU between these stages.\textsuperscript{18}

There is an urgent need to understand why patients are lost to follow-up.\textsuperscript{19,20} A better understanding of risk factors for tracing success and mortality among these patients could help to develop targeted interventions to prevent LTFU.\textsuperscript{21} This understanding may be achieved by describing the epidemiology and risk factors of LTFU. As the extent and causes of LTFU may differ between patients at different stages,\textsuperscript{17,18} the description should be made by stratifying patients into these groups. The aim of this study was to describe the epidemiology of LTFU including risk factors in patients at all stages of an HIV programme.

METHODS

Setting and patients
All patients treated according to the national guidelines from an HIV clinic at Hospital Nacional Simão Mendes (HNSM) in Bissau, the capital of Guinea-Bissau, were included in this retrospective cohort study. The outpatient ART centre of HNSM is the largest ART centre in Guinea-Bissau. The study population consisted of HIV-infected individuals diagnosed at the HIV clinic at HNSM between 1 June 2005 and 1 June 2012. Patients diagnosed with HIV in the period 1 March 2011 to 1 June 2012 who were not eligible to ART were excluded from the analyses, as they did not have 210 days of follow-up and could therefore not be considered either LTFU or on follow-up.

At the first visit to the clinic, HIV testing was performed and basic demographic information was collected. Schooling was defined as attending classes with the purpose of learning how to read; Koranic schools were not included in this definition. At the day of HIV diagnosis, patients were given a requisition for laboratory analyses (CD4 cell count, biochemistry and haematology). The blood samples were usually drawn at the clinic the following day and the patients were asked to return to the clinic within 7 days. At this consultation, the decision to initiate ART was made based on WHO guidelines. If ART initiation was decided, the patients received ART the same day as the consultation. All services, including ART, were free of charge for all HIV-infected patients.

Active follow-up
When diagnosed with HIV, the patients were provided with a unique registration number and a personal card stating the date of next appointment at the clinic. At HIV diagnosis, all patients were asked to provide their own telephone number and the number of a contact person to be used during active follow-up. Patients on ART were contacted if they had not been at the clinic for 3 months after the date of the last visit, and patients not eligible for ART were contacted if they had not been at the clinic for 180 days. Patient contact by telephone was attempted at least twice on two separate days.

Loss to follow-up
Patients on ART were considered lost to follow-up if they had not visited the clinic for 90 days (60 days after the next appointment), while patients without treatment were noted as LTFU if they had not been at the clinic for 7 months (1 month after the date of the next appointment). Information on patient mortality and clinic transfer was collected by personal information and telephone calls with contact persons and from the hospital wards. Patient confidentiality was at no point broken.

Laboratory methods
Venous blood samples were collected for biochemical analyses (alanine aminotransferase, aspartate transaminase, creatinine) and haematology (haemoglobin, CD4 cell count, platelets). Orphéex, Mythic, Diamond Diagnostics, USA was used to measure haematology. For biochemical analyses, the Reflotron Plus System, Roche diagnostics or BA-88 Mindray biochemical analyser was used. CD4 cell counts were performed by flow cytometry using Partec CyFlow SL_3 (Cyflow SL, Partec, Münster, Germany). HIV screening was carried out with a rapid test in the clinic (Determine HIV-1/2 assay (Abbott Laboratories, 72 Abbott Park, Illinois, USA) and confirmation and discrimination using SD Bioline HIV 1/2 3.0 (Standard Diagnostics Inc, Kyonggi-do, South Korea). As confirmation, an additional Bioline test was performed at the National Public Health Laboratory according to the standard recommendations from the National HIV programme of Guinea-Bissau.

Statistical methods
We compared the demographic, clinical and laboratory features of patients on or without ART using $\chi^2$ test for categorical variables. Continuous variables were compared using the two-sample t test (normal distribution) or Wilcoxon rank-sum test (non-normal distribution). Abnormal biochemical and haematological values were defined in accordance with the reference levels used at HNSM. Logistic regression was used for the analysis of
risk factors for LTFU among patients lost to programme before a follow-up consultation after CD4 measurement. The Cox proportional hazard model was used to calculate LTFU risk factors among patients not eligible for ART and patients on ART. Patients on ART were included in the regression analysis by the date of ART initiation. Follow-up time until ART initiation was included in the analysis of patients not eligible for ART. Variables associated with LTFU in the univariate model (p<0.10) were included in a multivariate model. In case of missing data, a ‘missing data’ group was made and included in the analysis to avoid exclusion of patients. Patients who died or were transferred to another HIV clinic were censored by the estimated time of death and time of transfer, respectively. The remaining patients were censored on 1 September 2012. The incidence rates (IR) of LTFU were calculated by Poisson regression analysis. To include all patients in the calculation of the overall IR of LTFU, the patients who had only been at the clinic on the day of HIV testing were considered to have 1 day of follow-up. All statistical analyses were carried out using Stata IC 11.0 (StataCorp, College Station, Texas, USA).

Ethical statement
The Bissau HIV cohort has been approved by the National Ethics Committee in Guinea-Bissau (Parcer NCP/No.15/2007). Upon inclusion, the patients provided a voluntary, signed and dated informed consent or a fingerprint if illiterate. The cohort has an open approval to use data from patients’ records as long as patient confidentiality is not broken.

Stages of LTFU
Loss to programme and LTFU could occur at four different stages (figure 1): LTFU immediately after HIV diagnosis (stage 1), LTFU after the first CD4 cell count and before a follow-up consultation (stage 2), LTFU after a follow-up consultation for patients not eligible for ART (stage 3) and LTFU among patients on ART (stage 4).

RESULTS
Baseline characteristics
Between June 2005 and June 2012, 4080 patients were diagnosed with HIV at HNSM; 2724 with HIV-1, 727 with HIV-2, 486 with HIV-1/2 and 143 with an unknown HIV type (table 1). Among the included 4080 patients, a significantly higher percentage of women than men were HIV-2 positive (20.2% vs 15.2%, p<0.01), and HIV-1 positive patients were more likely to be male than female (73.5% vs 67%, p<0.01). The overall mean age was 37.6 years (95% CI 37.2 to 37.9); age was significantly lower among HIV-1 infected (mean age 35.6 years) than HIV-2 infected patients (mean age 43.9 years, p<0.01). The mean age of HIV-1/2 dually infected patients was 39.4 years. In total, 3470 patients had a baseline CD4 measurement and the median CD4 cell count was 210 cells/μL (IQR 97–391). The HIV-2 infected patients had a significantly higher baseline CD4 cell count (median 260 cells/μL (IQR 115–491)) than the HIV-1 (median 202 cells/μL (IQR 89–362)) and HIV-1/2 dually infected patients (median 205 cells/μL, IQR 108–368 (p<0.01)).

Figure 1 Flow chart and outcome by 1 September 2012 of patients included in the study.
Patients not eligible for ART had 927.1 person-years of follow-up and the IR of LTFU was 35.2 (95% CI 31.5 to 39.2) per 100 person-years. Among patients on ART, the follow-up time was 4012.6 person-years and median time to ART initiation was 16 days (IQR 8–47). The IR of LTFU was 24.9 (95% CI 23.4 to 26.5) per 100 person-years. We stratified these findings by time period from the date of HIV diagnosis.

Six months after HIV diagnosis, 3329 (81.6%) of all patients diagnosed with HIV were on follow-up and 751 (18.4%) had been lost to the programme. Owing to the definition of LTFU among patients without ART (clinical absence for more than 210 days), all patients lost to follow-up within the first 6-month period were patients on ART. In this period, 325 (8%) patients had died, 66 (1.6%) patients had been transferred and 360 (8.8%) patients had been lost to follow-up.

In total, 3635 patients were diagnosed with HIV before September 2011; hence, a 1-year outcome could be evaluated. In all, 318 (8.7%) patients had died, 58 (1.6%) patients had been transferred and 1527 (42%) patients were lost to follow-up, leaving 1732 (47.6%) patients on follow-up.

Data on 2-year follow-up (HIV diagnosis before September 2010) were available for 2768 patients. In this patient group, 1715 (62%) patients had been lost to the programme and the remaining 1053 (38%) patients were still on follow-up. After 2 years, 258 (9.3%) patients had died, 55 (2%) patients had been transferred and 1402 (50.1%) patients were lost to follow-up.

### Risk factors of LTFU

Risk factors of LTFU among patients at stages 1–4 are presented in tables 2–5. Age below 30 years at inclusion was a risk factor among patients at all stages. No schooling was a significant risk factor among patients at stages 2 and 3, and among patients at stage 4 a positive trend was found (HR 1.22 (95% CI 0.98 to 1.52), p=0.08). The biggest risk factor at each stage was body mass index <18.5 kg/m² (stage 1: OR 2.92 (95% CI 1.32 to 6.43)), male gender (stage 2: OR 2.10 (95% CI 1.60 to 2.76)), HIV-2 infection (stage 3: HR 2.56 (95% CI 1.91 to 3.42)) and CD4 cell count <200 cells/μL (stage 4: HR 2.71 (95% CI 2.04 to 3.61)). Geographic site of residence was not associated with LTFU at any stage. Catholic patients had a lower risk of LTFU at stage 1 (OR 0.54 (95% CI 0.34 to 0.88)) and stage 4 (HR 0.75 (95% CI 0.59 to 0.96)), and patients with anaemia had a lower risk of LTFU at stage 3 (HR 0.32 (95% CI 0.23 to 0.45)).

### DISCUSSION

This retrospective cohort study investigated the outcome of 4080 HIV-positive patients, including a large proportion of HIV-2 infected patients, diagnosed at the largest HIV clinic in Bissau, Guinea-Bissau. Almost one-third of the patients had been lost to the programme before the first consultation where ART initiation was decided, and during the 7-year observation period more than half of the patients had been lost to follow-up. Age below
30 years at inclusion was a risk factor for LTFU at all stages. Among patients on ART, CD4 cell count <200 cells/μL was the strongest predictor of LTFU.

The main strength of this study is the large dataset with several years of follow-up. In contrast to this study, few sub-Saharan studies have addressed LTFU at all stages of the ART programme and provided risk factors of LTFU at all programme stages.17 Furthermore, active follow-up was limited to calling patients and/or their contact person by telephone as resource-limited settings often do not have the possibility to conduct home visits. This study resembles a frequent sub-Saharan setting and the rate of LTFU and its associations may resemble that of other clinics.

The study is limited by incomplete data among a substantial number of patients (table 1); this may have affected the analyses in either direction. Furthermore, HIV type discrimination was performed by SD Bioline HIV 1/2 3.0. A study from the neighbouring country Guinea-Conakry found that SD Bioline HIV 1/2 3.0 may have overestimated the number of HIV-1/2 dually infected patients;22 this was later confirmed in Guinea-Bissau.23

| Stage 1 LTFU risk factors | Logistic regression, LTFU OR | Multivariate analysis |
|--------------------------|----------------------------|----------------------|
|                          | Univariate analysis | p Value | OR (95% CI) | p Value | OR (95% CI) |
| Sex                      |                         |          |             |          |             |
| Male                     | 1.42 (1.14 to 1.76)    | <0.01    | 1.16 (0.75 to 1.82) | 0.50    |
| Female                   | 1.00                   |          | 1.00        |          |
| Age stratification (years) |                        |          |             |          |             |
| ≤30                      | 1.00                   |          | 1.00        |          |
| 30–39                    | 0.50 (0.39 to 0.65)    | <0.01    | 0.46 (0.18 to 0.77) | <0.01 |
| ≥40                      | 0.62 (0.48 to 0.79)    | <0.01    | 0.48 (0.27 to 0.85) | 0.01    |
| HIV type                 |                         |          |             |          |             |
| HIV-1                    | 1.00                   |          | 1.00        |          |
| HIV-2                    | 1.05 (0.78 to 1.41)    | 0.73     | 1.08 (0.64 to 1.83) | 0.77    |
| HIV-1/2                  | 1.38 (0.99 to 1.91)    | 0.06     | 2.49 (1.28 to 4.85) | <0.01  |
| Nutritional status (kg/m²) |                        |          |             |          |             |
| BMI≤18.5                 | 2.97 (1.36 to 6.48)    | <0.01    | 2.92 (1.32 to 6.43) | <0.01  |
| BMI>18.5                 | 1.00                   |          | 1.00        |          |
| Marital status           |                         |          |             |          |             |
| Single                   | 0.99 (0.78 to 1.27)    | 0.96     | 0.66 (0.41 to 1.06) | 0.08    |
| Married                  | 1.00                   |          | 1.00        |          |
| Divorced                 | 0.74 (0.46 to 1.17)    | 0.20     | 0.65 (0.28 to 1.52) | 0.32    |
| Widowed                  | 0.57 (0.41 to 0.80)    | <0.01    | 0.72 (0.38 to 1.37) | 0.32    |
| Religion                 |                         |          |             |          |             |
| Muslim                   | 1.00                   |          | 1.00        |          |
| Catholic                 | 0.73 (0.57 to 0.95)    | 0.02     | 0.54 (0.34 to 0.88) | 0.01    |
| Protestant               | 0.40 (0.23 to 0.67)    | <0.01    | 0.54 (0.21 to 1.38) | 0.20    |
| Animist                  | 0.88 (0.67 to 1.16)    | 0.37     | 1.09 (0.63 to 1.88) | 0.76    |
| Schooling                |                         |          |             |          |             |
| Yes                      | 1.00                   |          |             |          |
| No                       | 1.11 (0.89 to 1.38)    | 0.37     |             |          |
| Geographic site of residence |                       |          |             |          |             |
| Bissau                   | 1.00                   |          |             |          |
| Outside Bissau           | 0.34 (0.05 to 2.56)    | 0.30     |             |          |

BMI, body mass index; LTFU, loss to follow-up.

The prevalence of patients lost to follow-up was high in this study compared with several other African studies, but the heterogeneity in the definition of LTFU makes comparisons between studies difficult. Different LTFU definitions for patients on ART have been proposed ranging from 60 days after a missed appointment to 180 days after the last visit.24 25 HIV-infected patients at HNSM are usually supplied with ART for 30 days at a time. LTFU among patients on ART was defined as 90 days of absence from the date of the last visit. To our knowledge, there are no studies from sub-Saharan Africa regarding the ‘best performing’ definition of LTFU among HIV-infected patients before ART initiation.

In this study, mortality was rather low while LTFU was high. Other studies performed in Africa have found that mortality was inversely related to the rate of LTFU.3 Several of the LTFU risk factors among patients on ART were similar to the mortality risk factors among African HIV-infected patients as described elsewhere.26 27 If a more thorough follow-up had been performed in the study period, the mortality rate would presumably be higher.

Table 2 LTFU risk factors in patients without a CD4 cell count (stage 1)
In Guinea-Bissau, many people are involved in seasonal work, especially picking cashew in the country regions, which makes them leave the capital city Bissau during the cashew season. Furthermore, Guinea-Bissau has been considered politically unstable for many years. During the civil war in 1998–1999, a substantial part of the inhabitants of Bissau fleeing from the capital city,28 and several coup attempts since the clinic opened in 2005 may have influenced the degree of LTFU. However, we do not have precise data on why patients did not show up for appointments at the clinic.

Age below 30 years at inclusion was a risk factor for LTFU in all patients groups in our study. Furthermore, no schooling and male gender were risk factors at two stages. These variables have also been associated with LTFU in other studies.19 29–32 Owing to the consistency in these risk factors, special attention should be made to avoid LTFU among these patients.

HIV-2 infection was associated with LTFU among patients at stages 2–4. The progression of HIV-2 infection is generally much slower than that of HIV-1 and a large proportion of HIV-2 infected individuals do not progress to AIDS.33 A study from Gambia investigated pretreatment LTFU, but found no association between HIV-2 infection and LTFU,34 which is similar to LTFU at stage 1 in our study. At the baseline characteristics, HIV-2 was associated with a higher CD4 cell count. Patients with a high CD4 cell count may be prone to LTFU due to fewer HIV-related symptoms.35

### Table 3  LTFU risk factors in patients without a follow-up consultation after CD4 cell count (stage 2)

| Stage 2 | LTFU risk factors | Logistic regression, LTFU OR | p Value | Logistic regression, LTFU OR | p Value |
|---------|------------------|-----------------------------|---------|-----------------------------|---------|
|         |                  | Univariate analysis         |         | Multivariate analysis       |         |
|         |                  | OR (95% CI)                 | p Value | OR (95% CI)                 | p Value |
| Sex     | Male             | 1.47 (1.17 to 1.84)         | <0.01   | 2.10 (1.60 to 2.76)         | <0.01   |
|         | Female           | 1.00                        |         | 1.00                        |         |
| Age stratification (years) | ≤30 | 1.00                        |         | 1.00                        |         |
|         | 30–39            | 0.74 (0.57 to 0.96)         | 0.03    | 0.58 (0.43 to 0.79)         | <0.01   |
|         | ≥40              | 0.71 (0.55 to 0.93)         | 0.01    | 0.46 (0.33 to 0.65)         | <0.01   |
| HIV type| HIV-1            | 1.00                        |         | 1.00                        |         |
|         | HIV-2            | 1.44 (1.09 to 1.90)         | 0.01    | 1.58 (1.14 to 2.19)         | <0.01   |
|         | HIV-1/2          | 1.38 (0.98 to 1.93)         | 0.06    | 1.58 (1.09 to 2.30)         | 0.02    |
| CD4 cell count (cells/μL) | ≤200 | 0.59 (0.46 to 0.75)         | <0.01   | 0.56 (0.42 to 0.74)         | <0.01   |
|         | 201–350          | 0.41 (0.31 to 0.56)         | <0.01   | 0.45 (0.32 to 0.62)         | <0.01   |
|         | >350             | 1.00                        |         | 1.00                        |         |
| Anaemia* | Yes             | 1.00 (0.68 to 1.48)         | 1.00    | –                           | –       |
|         | No               | 1.00                        |         | –                           | –       |
| Nutritional status (kg/m²) | BM1≤18.5 | 1.29 (0.97 to 1.72)         | 0.08    | 1.32 (0.97 to 1.79)         | 0.08    |
|         | BM1>18.5         | 1.00                        |         | 1.00                        |         |
| Marital status | Single | 0.97 (0.75 to 1.26)         | 0.83    | –                           | –       |
|         | Married          | 1.00                        |         | –                           | –       |
|         | Divorced         | 1.07 (0.69 to 1.66)         | 0.78    | –                           | –       |
|         | Widowed          | 0.76 (0.55 to 1.06)         | 0.11    | –                           | –       |
| Religion | Muslim          | 1.00                        |         | 1.00                        |         |
|         | Catholic         | 0.86 (0.66 to 1.13)         | 0.28    | 0.93 (0.68 to 1.27)         | 0.64    |
|         | Protestant       | 0.57 (0.35 to 0.94)         | 0.03    | 0.63 (0.36 to 1.09)         | 0.10    |
|         | Animist          | 0.89 (0.66 to 1.19)         | 0.42    | 0.85 (0.61 to 1.17)         | 0.32    |
| Schooling | Yes             | 1.00                        |         | 1.00                        |         |
|         | No               | 1.27 (1.01 to 1.60)         | 0.04    | 1.80 (1.35 to 2.40)         | <0.01   |
| Geographic site of residence | Bissau | 1.00                        |         | –                           | –       |
|         | Outside Bissau   | 1.22 (0.81 to 1.81)         | 0.34    | –                           | –       |

*Haemoglobin below normal range: men >13 mg/dl, women >12 mg/dl.

BMI, body mass index; LTFU, loss to follow-up.
Anaemia seemed to have a protective effect among patients with LTFU at stage 3. Patients at this stage had a CD4 cell count >350 cells/μL and were not eligible for ART according to national guidelines. Low haemoglobin may have caused these patients to feel ill despite a higher CD4 cell count, and thus motivated patients to adhere to the HIV clinic. Differences in risk factors of LTFU in patient at stages 1–4 may be due to the differences in causes of LTFU.

Various approaches have been tried to reduce the rate of LTFU including adherence support workers\(^\text{36}\) and mobile telephone messaging,\(^\text{37}\) but resource-limited settings may not have the economy to support this without increasing external donor support. Treating the maximal number of new patients possible has been the top priority for many public sector programmes, with the possible consequence that documenting and tracing patients with LTFU have become increasingly inadequate.\(^\text{38}\) Interventions that prevent LTFU in resource-limited settings can substantially improve survival and may be cost-effective by international criteria. HIV treatment in these settings should include interventions to prevent LTFU.\(^\text{39}\)

During the last decade, the CD4 cell count threshold for ART initiation has risen steadily. A recent study found ART initiation among patients with a CD4 cell count >500/μL to be beneficial based on the level of HIV RNA suppression\(^\text{40}\) and early ART initiation among these patients has also been shown to have an enhanced recovery of CD4 cell counts.\(^\text{41}\) Although the patient groups are not directly comparable, the IR of LTFU among patients not eligible for ART was higher than that of patients on ART. However, we are not aware of any studies evaluating the effect of early ART on LTFU in sub-Saharan Africa.

This study does not provide the causes of LTFU among HIV-infected patients in Guinea-Bissau. Social workers visiting the homes of patients may be used to identify reasons why patients are lost to follow-up. Understanding the reasons for LTFU is crucial for developing effective strategies to prevent it.

### Table 4 LTFU risk factors in patients not eligible for antiretroviral treatment (stage 3)

| Stage 3 LTFU risk factors | Cox regression, LTFU hazard rates (HR) |  |
|---------------------------|----------------------------------------|---|
|                          | Univariate analysis                     | Multivariate analysis |
|                          | HR (95% CI) | p Value | HR (95% CI) | p Value |
| Sex                       |            |         |            |         |
| Male                      | 0.93 (0.72 to 1.20) | 0.59 | – | – |
| Female                    | 1.00 | – | – | – |
| Age stratification (years) |            |         |            |         |
| ≤30                       | 1.00 | – | 1.00 | – |
| 30–39                     | 0.74 (0.56 to 0.97) | 0.03 | 0.54 (0.40 to 0.73) | <0.01 |
| ≥40                       | 0.85 (0.65 to 1.10) | 0.21 | 0.52 (0.38 to 0.71) | <0.01 |
| HIV type                  |            |         |            |         |
| HIV-1                     | 1.00 | – | 1.00 | – |
| HIV-2                     | 1.33 (1.04 to 1.69) | 0.02 | 2.56 (1.91 to 3.42) | <0.01 |
| HIV-1/2                   | 0.83 (0.56 to 1.23) | 0.37 | 0.93 (0.61 to 1.42) | 0.75 |
| Anaemia*                  |            |         |            |         |
| Yes                       | 0.54 (0.40 to 0.72) | <0.01 | 0.32 (0.23 to 0.45) | <0.01 |
| No                        | 1.00 | – | 1.00 | – |
| Nutritional status (kg/m²) |            |         |            |         |
| BMI≤18.5                  | 1.19 (0.91 to 1.55) | 0.20 | – | – |
| BMI>18.5                  | 1.00 | – | – | – |
| Marital status            |            |         |            |         |
| Single                    | 0.92 (0.69 to 1.21) | 0.54 | – | – |
| Married                   | 1.00 | – | – | – |
| Divorced                  | 1.03 (0.65 to 1.62) | 0.91 | – | – |
| Widowed                   | 1.06 (0.78 to 1.44) | 0.70 | – | – |
| Religion                  |            |         |            |         |
| Muslim                    | 1.00 | – | – | – |
| Catholic                  | 0.91 (0.69 to 1.19) | 0.48 | – | – |
| Protestant                | 1.16 (0.76 to 1.78) | 0.50 | – | – |
| Animist                   | 1.02 (0.76 to 1.36) | 0.92 | – | – |
| Schooling                 |            |         |            |         |
| Yes                       | 1.00 | – | 1.00 | – |
| No                        | 1.48 (1.18 to 1.86) | <0.01 | 1.37 (1.07 to 1.77) | 0.01 |
| Geographic site of residence |          |         |            |         |
| Bissau                    | 1.00 | – | – | – |
| Outside Bissau            | 1.26 (0.91 to 1.75) | 0.17 | – | – |

*Haemoglobin below normal range: men >13 and women >12 mg/dL.

BMI, body mass index; LTFU, loss to follow-up.
clarify the causes of absence, but due to a lack of social security numbers, street names and house numbers in many countries with limited resources, follow-up is difficult. Therefore, demographic surveillance sites (DSS) are well suited to long-term follow-up of HIV-infected individuals. We are currently undertaking a nested follow-up study of the cohort patients living in a DSS area in Guinea-Bissau.

CONCLUSION
In our study, we found a high rate of LTFU and some variation in the risk factors of LTFU, which may be due to different causes of LTFU at the different stages of the HIV programme. As the mortality among patients lost to follow-up regardless of ART status is substantial, an increased focus on patient retention is recommended.

Author affiliations
1 Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau
2 Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark
3 National HIV Programme, Ministry of Health, Bissau, Guinea-Bissau
4 National Public Health Laboratory, Bissau, Guinea-Bissau
5 GloHAU, Center for Global Health, School of Public Health, Aarhus University, Aarhus, Denmark

Acknowledgements The authors are grateful to the patients for their willingness to participate. Special thanks to the clinic assistants Aminata, Quintero, Marques, Joao, Imbemba and the rest of the staff working in the HIV clinic at HNSM for their dedication to work and kindness with patients. They are also grateful to the laboratory staff working in the TB and HIV programme.

Table 5 LTFU risk factors in patients on antiretroviral treatment (stage 4)

| LTFU risk factors | Cox regression, LTFU hazard rates (HR) |
|-------------------|---------------------------------------|
|                   | Univariate analysis | Multivariate analysis |
|                   | HR (95% CI) | p Value | HR (95% CI) | p Value |
| Sex               |           |         |           |         |
| Male              | 1.21 (1.06 to 1.38) | <0.01 | 1.41 (1.15 to 1.74) | <0.01 |
| Female            | 1.00 | – | 1.00 | – |
| Age stratification (years) |         |         |           |         |
| ≤30               | 1.00 | – | 1.00 | – |
| 30–39             | 0.83 (0.71 to 0.97) | 0.02 | 0.68 (0.54 to 0.86) | <0.01 |
| ≥40               | 0.83 (0.71 to 0.97) | 0.02 | 0.62 (0.48 to 0.79) | <0.01 |
| HIV type          |           |         |           |         |
| HIV-1             | 1.00 | – | 1.00 | – |
| HIV-2             | 1.12 (0.95 to 1.33) | 0.17 | 1.39 (1.08 to 1.80) | 0.01 |
| HIV-1/2           | 1.22 (1.02 to 1.46) | 0.03 | 1.65 (1.24 to 2.18) | <0.01 |
| CD4 cell count (cells/μL) |       |         |           |         |
| <200              | 2.05 (1.63 to 2.56) | <0.01 | 2.71 (2.04 to 3.61) | <0.01 |
| 201–350           | 1.83 (1.44 to 2.31) | <0.01 | 2.31 (1.71 to 3.13) | <0.01 |
| >350              | 1.00 | – | 1.00 | – |
| Anaemia*          |           |         |           |         |
| Yes               | 1.19 (0.95 to 1.48) | 0.13 | – | – |
| No                | 1.00 | – | – | – |
| Nutritional status (kg/m²) |       |         |           |         |
| BMI≤18.5          | 1.58 (1.38 to 1.81) | <0.01 | 1.51 (1.23 to 1.87) | <0.01 |
| BMI>18.5          | 1.00 | – | 1.00 | – |
| Marital status    |           |         |           |         |
| Single            | 0.96 (0.82 to 1.11) | 0.57 | – | – |
| Married           | 1.00 | – | – | – |
| Divorced          | 0.80 (0.60 to 1.08) | 0.15 | – | – |
| Widowed           | 0.91 (0.76 to 1.09) | 0.31 | – | – |
| Religion          |           |         |           |         |
| Muslim            | 1.00 | – | 1.00 | – |
| Catholic          | 0.74 (0.63 to 0.87) | <0.01 | 0.75 (0.59 to 0.96) | 0.02 |
| Protestant        | 0.79 (0.61 to 1.03) | 0.08 | 0.79 (0.54 to 1.15) | 0.21 |
| Animist           | 0.98 (0.84 to 1.15) | 0.83 | 1.09 (0.86 to 1.39) | 0.47 |
| Schooling         |           |         |           |         |
| Yes               | 1.00 | – | 1.00 | – |
| No                | 1.21 (1.06 to 1.38) | <0.01 | 1.22 (0.98 to 1.52) | 0.08 |
| Geographic site of residence |       |         |           |         |
| Bissau            | 1.00 | – | – | – |
| Outside Bissau    | 1.06 (0.85 to 1.31) | 0.61 | – | – |

*Haemoglobin below normal range: men >13 and women >12 mg/dL.
BMI, body mass index; LTFU, loss to follow-up.
sections at the National Public Health Laboratory and to the office staff at the Bandim Health Project for making this study possible. The authors would like to thank Ole Schmeltz Segaa and Lars Skov Dalgaard for epidemiological advice and Peter Aaby for insisting on focusing on follow-up.

**Collaborators**

The Bissau HIV cohort study group comprises: Amabelia Rodrigues, David da Silva, Zacarias da Silva, Candida Medina, Ines Oliveira-Souto, Lars Østergaard, Alex Laursen, Morten Sodemann, Peter Aaby, Anders Fomsgaard, Christian Erikstrup, Jesper Eugen-Olsen and Christian Wejse (chair).

**Contributors**

The study was planned by BLH, SJ, ALL, CW, PBN and LØ, and executed by BLH. BLH, SJ and CW were responsible for the statistical analyses. SJ, PBN, CW and ALL were involved in the interpretation of data. CM and DdaS carried out patient consultations. ZIdaS was responsible for the laboratory test strategies. CM and DdaS were responsible for the logistical work at the outpatient ART-NHSM. BLH wrote the first draft and all authors contributed to the final version of the paper.

**Funding**

The study was supported by the Bandim health project, ‘Overlæge Johan Boserup og Lise Boserups Legat’ and ‘Aase og Ejnar Danielsen Fond’. The Global Fund to Fight AIDS, TB and Malaria (Global Fund) supported the data collection during 2009–2013 through the ‘Secretariado Nacional de Luta contra o Sida’ in Guinea-Bissau. The Ministry of Foreign Affairs of Denmark (DANIDA) provided a travel grant for BLH, and Aarhus University, Denmark supported a 1-year scholarship for BLH. WAPHIR and IeDEA supported data collection in Bissau.

**Competing interests**

None.

**Patient consent**

Obtained.

**Ethics approval**

National Ethics Committee in Guinea-Bissau.

**Provenance and peer review**

Not commissioned; externally peer reviewed.

**Data sharing statement**

All data from this original research article may be shared on publication. Data collection is continuously gathered and entered into the database at the HIV clinic, Hospital Nacional Simão Mendes in Bissau, Guinea-Bissau. No additional data are freely available. Access to the database may be granted by contacting the corresponding author.

**Open Access**

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

**REFERENCES**

1. UNAIDS Data Tables 2011. http://www.unaids.org/en/media/unaids/ contentassets/documents/unaidspublication/2011/JC2225_UNAIDS.databables_en.pdf (accessed 4 Jun 2013).
2. May M, Sterne JA, Sabin C, et al. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 2007;21:1185–97.
3. Brinkhof MW, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS ONE 2009;4:e5790.
4. Ouygi JH, Byakika-Tusime J, Ragnold K, et al. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS 2007;21:965–71.
5. Adje C, Cheingsong R, Roels TH, et al. High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Cote d’Ivoire. J Acquir Immune Defic Syndr 2001;26:501–6.
6. Mugusi F, Mugusi S, Bakari M, et al. Enhancing adherence to antiretroviral therapy at the HIV clinic in resource constrained countries; the Tanzanian experience. Trop Med Int Health 2009;14:1226–32.
7. Bartlett JA, Shao JF. Successes, challenges, and limitations of current antiretroviral therapy in low-income and middle-income countries. Lancet Infect Dis 2009;9:637–49.
8. Brinkhof MW, Dabis F, Myer L, et al. Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower income countries. Bull World Health Organ 2008;86:497–576.
9. Rosens S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med 2007;4:e298.
10. ANW, Frangakis CE, Musick BS, et al. The need for double-sampling designs in survival studies: an application to monitor PEPFAR. Biometrics 2009;65:301–6.
11. Bisson GP, Gaoalthe T, Gross R, et al. Overestimates of survival after HAART: implications for global scale-up efforts. PLoS ONE 2008;3:e1725.
12. Ulett KB, Willig JH, Lin HY, et al. The therapeutic implications of timely linkage and early retention in HIV care. AIDS Patient Care STDS 2009;23:41–9.
13. Sterne JA, May M, Costagliola D, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009;373:1352–63.
14. Larson BA, Brennan A, McNamara L, et al. Early loss to follow-up after enrolment in pre-ART care at a large public clinic in Johannesburg, South Africa. Trop Med Int Health 2010;15:43–7.
15. Serron B, Nkanza M, Birungi J, et al. Mortality and loss-to-follow-up during the pre-treatment period in an antiretroviral therapy programme under normal health service conditions in Uganda. BMC Public Health 2009;9:290.
16. Togon T, Petersen I, Jaffar S, et al. Pre-treatment mortality and loss-to-follow-up in HIV-1, HIV-2 and HIV-1/HIV-2 dually infected patients eligible for antiretroviral therapy in the Gambia, West Africa. AIDS Res Ther 2011;8:24.
17. Mugglin C, Estill J, Wandelger G, et al. Loss to programme between HIV diagnosis and initiation of antiretroviral therapy in sub-Saharan Africa: systematic review and meta-analysis. Trop Med Int Health 2012;17:1509–20.
18. Rosens S, Fox MP. Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med 2011;8:e1001056.
19. Ochieng-Ooko V, Ochieng D, Sidje JE, et al. Influence of gender on loss to follow-up in a large HIV treatment programme in western Kenya. Bull World Health Organ 2010;88:681–8.
20. Geng EH, Bangsberg DR, Musinguzi N, et al. Understanding the reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programmes in Africa through a sampling-based approach. J Acquir Immune Defic Syndr 2010;53:405–11.
21. Brinkhof MW, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource limited settings: systematic review and meta-analysis. PLoS ONE 2009;4:e5790.
22. Chaillet P, Tayler-Smith K, Zachariah R, et al. Evaluation of four rapid tests for diagnosis and differentiation of HIV-1 and HIV-2 infections in Guinea-Conakry, West Africa. Trans R Soc Trop Med Hyg 2010;104:571–6.
23. Hengle BL, BJarmason MPO, Jespersen S, et al. Performance of three rapid tests for discrimination between HIV-1 and HIV-2 in Guinea-Bissau, West Africa. J Acquir Immune Defic Syndr [Epub ahead of print 26 Aug 2013].
24. Chi BH, Yanniouotos CT, Westfall AO, et al. Universal definition of loss to follow-up in HIV treatment programs: a statistical analysis of 111 facilities in Africa, Asia, and Latin America. PLoS Med 2011;8:e1001111.
25. Chi BH, Cantrell RA, Mwango A, et al. An empirical approach to defining loss to follow-up among patients enrolled in antiretroviral treatment programs. Am J Epidemiol 2010;171:924–31.
26. Erikstrup C, Kallestrup P, Zinyama R, et al. Predictors of mortality in a cohort of HIV-1 infected adults in rural Uganda. J Acquir Immune Defic Syndr 2007;44:780–3.
27. Oliviera I, Andersen A, Furtado A, et al. Assessment of simple risk markers for early mortality among HIV-infected patients in Guinea-Bissau: a cohort study. BMJ Open 2012;2:e001587.
28. Nielsen J, Jensen H, Andersen PK, et al. Mortality patterns during a war in Guinea-Bissau 1998–99: changes in risk factors? Int J Epidemiol 2006;35:438–46.
29. Karcher H, Omondi A, Odora J, et al. Risk factors for treatment denial and loss to follow-up in an antiretroviral treatment cohort in Kenya. Trop Med Int Health 2007;12:687–94.
30. Bygrave H, Mbuga M, Ncube K, et al. Antiretroviral therapy outcomes among adolescents at youth in rural Zimbabwe. PLoS ONE 2012;7:e52856.
31. Soni G, Keogh SC, Todd J, et al. Low mortality risk but high loss to follow-up among patients in the Tanzanian national HIV care and treatment programme. Trop Med Int Health 2012;17:497–506.
32. Onoka CA, Uzochukwu BS, Onwujekwe OE, et al. Retention and loss to follow-up in antiretroviral treatment programmes in southeast Nigeria. Pathog Glob Health 2012;106:46–54.

33. Marlink R, Kanki P, Thor I, et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 1994;265:1587–90.

34. Togun T, Peterson I, Jaffar S, et al. Pre-treatment mortality and loss-to-follow-up in HIV-1, HIV-2 and HIV-1/HIV-2 dually infected patients eligible for antiretroviral therapy in The Gambia, West Africa. AIDS Res Ther 2011;8:24.

35. Lewden C, Gabillard D, Minga A, et al. CD4-specific mortality rates among HIV-infected adults with high CD4 count and no antiretroviral treatment in West Africa. J Acquir Immune Defic Syndr 2012;59:213–19.

36. Torpey KE, Kabaso ME, Mutale LN, et al. Adherence support workers: a way to address human resource constraints in antiretroviral treatment programs in the public health setting in Zambia. PLoS ONE 2008;3:2204.

37. Lester RT, Ritvo P, Mills EJ, et al. Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WeTel Kenya1): a randomized trial. Lancet 2010;376:1838–45.

38. Myer L, el-Sadr W. Expanding access to antiretroviral therapy through the public sector—the challenge of retaining patients in long-term primary care. S Afr Med J 2004;94:273–4.

39. Losina E, Touré H, Uhler LM, et al. Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Côte d’Ivoire appraisal. PLoS Med 2009;6:e1000173.

40. Geng EH, Hare CB, Kahn JO, et al. The effect of a “Universal Antiretroviral Therapy” recommendation on HIV RNA levels among HIV-infected patients entering care with a CD4 count greater 500/μl in a public health setting. Clin Infect Dis 2012;12:1690–7.

41. Le T, Wright EJ, Smith DM, et al. Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. N Engl J Med 2013;368:218–30.

42. da Silva ZJ, Oliveira I, Andersen A, et al. Changes in prevalence and incidence of HIV-1, HIV-2 and dual infections in urban areas of Bissau, Guinea-Bissau: is HIV-2 disappearing? AIDS 2008;22:1195–202.